Idiopathic pulmonary fibrosis (IPF) is a chronic progressive disease of unknown cause
characterized by relentless scarring of the lung parenchyma leading to reduced quality of life and …

Large multicenter clinical trials have led to two recently approved drugs for patients with
idiopathic pulmonary fibrosis (IPF); yet, both of these therapies only slow disease progression …

Interstitial lung diseases (ILDs), which can arise from a broad spectrum of distinct aetiologies,
can manifest as a pulmonary complication of an underlying autoimmune and connective …

Rationale: Idiopathic pulmonary fibrosis (IPF) is a chronic, progressive, and usually lethal
fibrotic lung disease characterized by profound changes in epithelial cell phenotype and …

Thyroid hormone (TH) is critical for the maintenance of cellular homeostasis during stress
responses, but its role in lung fibrosis is unknown. Here we found that the activity and …

Idiopathic pulmonary fibrosis (IPF) is a chronic, progressive, fibrotic form of diffuse lung disease
occurring mainly in older adults. Increased lysophosphatidic acid (LPA) concentrations …

Rationale: The implication of T cells in the pathogenesis of idiopathic pulmonary fibrosis (IPF)
is controversial. CD4 + CD25 + FOXP3 + regulatory T cells (Tregs) are pivotal in …

Idiopathic pulmonary fibrosis (IPF) is a chronic fibrotic lung disease of unknown etiology. With
a gradually increasing worldwide prevalence and a mortality rate exceeding that of many …

Idiopathic pulmonary fibrosis (IPF) is a highly heterogeneous, unpredictable and ultimately
lethal chronic lung disease. Over the last decade, two anti-fibrotic agents have been shown to …

Idiopathic pulmonary fibrosis (IPF) is the most common and lethal form of idiopathic interstitial
pneumonia. The disease, which occurs primarily in middle-aged and older adults, is …